We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Social Diagnostics Start-Up to Provide Simple, Affordable Tests Worldwide

By LabMedica International staff writers
Posted on 18 Aug 2014
The Royal Tropical Institute (KIT; Amsterdam, Netherlands) is establishing a nonprofit, social diagnostics company that develops and markets tests for the diagnosis of poverty-related diseases.

Infectious diseases have a global impact; they take no account of national borders and influence the stability of societies in matters of health and development. More...
Paul Klatser, unit manager at KIT Biomedical Research and Donald Kalff, investor and formerly a director at KLM and Shell, have joined forces in taking the initiative to establish "OneDiagnostics," with the ambition to improve the health of disadvantaged people worldwide. “I consider it a moral obligation to develop and share this type of knowledge. Both the private sector and governments are failing with regard to their support. In the Netherlands it is inconceivable to prescribe antibiotics for a fever without first having been examined by a doctor. This is however often the case in low- and middle-income countries. Not only does this leave people to remain ill or even die, it also increasingly leads to antibiotic resistance," said Mr. Klatser.

"In the ‘Western world’ we have the knowledge to treat most diseases effectively—with a timely diagnosis. The required medicines are affordable and available, also in low- and middle-income countries" said Mr. Klatser. "We are not restricting ourselves to only developing simple tests. We will also market them and invest in the correct provision of information about diagnostics and treatment, and our ultimate goal is local development and production.”

OneDiagnostics expects to need EUR 2.5 million for the start-up of the company. This would make it possible to market the first tests for brucellosis, leptospirosis, typhoid fever, and leishmaniasis. There are more plans, such as low-cost tests for tuberculosis, malaria, and a combined test for HIV and syphilis, especially intended for pregnant women in developing countries.

“We have a business plan and are now working hard to find funds to make a good start and we hope that investors will receive a small financial return in the future," said Mr. Klatser, "We will provide affordable, quality products with honest, scientifically substantiated information. The real benefit lies in the difference that OneDiagnostics will make with respect to the health of millions.”

Related Links:

Royal Tropical Institute (KIT)



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Spinal Fluid Cell Count Control
Spinalscopics
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.